Efficacy and safety of relacorilant for the treatment of patients with Cushing’s syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

By afschroeder • February 24, 2026

Pivonello R, Arnaldi G, Auchus RJ, Badiu C, Busch RS, Cannavò S, Dischinger U, Dobri GA, Donegan DM, Elenkova A, Fazeli PK, Feelders RA, Garcia-Centeno R, Gilis-Januszewska A, Hamidi O, Hannoush ZC, Kargi AY, Miller HJ, Ranetti AE, Recasens M, Reincke M, Rovner S, Salvatori R, Silverstein J, Stigliano A, Terzolo M, Wang C, Yuen KCJ, Kesner-Hays A, Hand AL, Tudor IC, Araque KA, Moraitis AG; GRACE Study Investigators. Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. Lancet Diabetes Endocrinol. 2026 Feb 20:S2213-8587(25)00362-6. doi: 10.1016/S2213-8587(25)00362-6. Epub ahead of print. PMID: 41730814.

Tags: Endocrinology, Harbor UCLA, Publications

Stabilizing and strengthening the U.S. physician-scientist faculty workforce in academic medicine: a proposed institutional framework

Williams CS, Allen M, Cooper Byas P, Hawley JB, Muglia LJ, Abel ED, Bastarache JA, Calfee CS, Carethers JM, Cornfield DN, Eickelberg O, Gallagher EJ,[...]

The effectiveness of care coordination on medication adherence among high-need, high-cost commercially insured beneficiaries: A randomized controlled trial

Saju R, Harwood JM, Tseng CH, Moin T, Mangione C, Duru OK, Takada S, Onufrak S. The effectiveness of care coordination on medication adherence among[...]

Systems Genetics Reveals ITIH5 as a Key Mediator of Adipocyte-Endothelial Crosstalk

Zhou M, Velez LM, Kwan D, Moses L, Johnson CD, Nguyen CM, Mott L, Gamie F, Fouladi M, Bae H, Verlande A, Arneson D, Petrus[...]